Login
Need to Register?   Forgot Password?
Dynamic Slide Library Index


CCMD SLIDES: CREATED BY CCMD

Atherosclerotic Progression/Regression
Atherosclerotic Progression/ Regression
Lp(a): Vascular Events by Sex and Quintile at Baseline (Cardiovascular Health Study)
CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C
L-CAD: Comparison of End Points, Change in Lumen Diameters
PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis
PDAY: Prevalence of lesions in LAD
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
Post-CABG Study: Aggressive vs Moderate Treatment
Post-CABG: End Points, Results, Conclusions
Post-CABG Angiographic Outcomes
Post-CABG: Event Rates by Cholesterol Group
Effect of Lifestyle Changes on Angiographic CAD
Coronary Artery Calcification (CAC) and CHD Family History
Ethnic Disparities in CVD Risk Factors in the US Population
US Death Rates From CVD by Ethnicity and Sex, 1980-2001
Smoking-Related CV Mortality in Year 2000
Trends in Total Cholesterol for US Adults, 1960-1962 to 1999-2002
WISE Study: Review of Ischemic Heart Disease in Women
Trans-Fatty Acid Intake and Relative Risk for CHD
Endothelial Dysfunction: A Barometer of Cardiovascular Risk?
Association Between Change in Lumen Size and Coronary Events: Important Factors
The Matrix Skeleton of Unstable Coronary Artery Plaque
Characteristics of Plaques Prone to Rupture
TGs Predict CAD Risk Independently of TC and HDL-C
Association of Small, Dense LDL With Myocardial Infarction
Responses to a 75-g Oral Glucose Challenge in Relation to LDL Particle Diameter
Cumulative Distribution of Adjusted Plasma TG Levels: LDL Phenotypes A and B
Cumulative Distribution of Adjusted HDL-C: LDL Phenotypes A and B
Composite CIMT With Metabolic Syndrome in Young Adults
Progression to Atherosclerotic Clinical Events in Patients With Diabetes
Atherosclerosis in Diabetes
Potential Mechanisms of Atherogenesis in Diabetes
Association of Subclinical Atherosclerosis Outcomes With 10-Year FRS
CAC Cutoffs by 10-Year CHD Event Risk Among CVD-Free Subjectsa
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C: 5-Year Follow-Up


Clinical Guidelines
ATP III
ATP III: Features Shared With ATP II
ATP III: LDL-C, HDL-C, TC Classification
ATP III: Major CHD Risk Factors Other Than LDL-C
ATP III: Additional CHD Risk Factors
ATP III: Assessment of Risk
ATP III: Risk Categories, LDL-C Goals
ATP III: CHD Risk Equivalents
ATP III: LDL-C Treatment Cutpoints for Therapy
ATP III: Nutritional Components of the TLC Diet
ATP III: Additional Dietary Options for LDL-C Lowering
ATP III: Management of Elevated TG
ATP III: The Metabolic Syndrome
ATP III: Management of Diabetic Dyslipidemia
ATP III: LDL-C Measurements in Patients Hospitalized for Major Coronary Events
ATP III: Special Populations—Women, Middle-Aged Men
ATP III: Improving Adherence—Focus on the Patient
ATP III: Improving Adherence—Focus on the Physician, Delivery System
ATP III Framingham Risk Scoring–Assessing CHD Risk in Men
ATP III Framingham Risk Scoring–Assessing CHD Risk in Women
ATP III Framingham Risk Scoring–Step 1: Age
ATP III Framingham Risk Scoring–Step 2: Total Cholesterol
ATP III Framingham Risk Scoring–Step 3: HDL-Cholesterol
ATP III Framingham Risk Scoring–Step 4: Systolic Blood Pressure
ATP III Framingham Risk Scoring–Step 5: Smoking Status
ATP III Framingham Risk Scoring Step 6: Adding Up the Points (Sum From Steps 1–5)
ATP III Framingham Risk Scoring–Step 7: CHD Risk for Women
ATP III Framingham Risk Scoring Step 7: CHD Risk for Men
Update to ATP III Guidelines: Rationale
Update to ATP III Guidelines: Rationale (cont'd)
ATP III: Updated LDL-C Goals, Treatment Cutpoints
ATP III: Updated LDL-C Goals, Treatment Cutpoints (cont'd)
ATP III: Management of Low HDL-C
ATP III: Special Populations—Older Adults, Younger Adults
ATP III vs ATP II: Increases in Treatment-Eligible Primary-Prevention Patients
Other
AHA Evidence-Based Guidelines for CVD Prevention in Women (cont'd)
Cost of CHD in the United States
Cost of CVD and Stroke in the United States
US Cost of Health Expenditures, Lost Productivity of CVD and Stroke
JNC 7: Treatment Algorithm for Hypertension
AHA/CDC Panel: Recommendations for Use of hs-CRP in Clinical Practice
AHA/CDC Panel: Recommendations for hs-CRP Laboratory Testing
Prevalence of Class 3 Obesity in the United States: BRFSS 2000
BMI: Adjusted Odds Ratios for Unstable Coronary Artery Disease
AHA Get With the Guidelines: Adherence to Treatment Measures
AHA Evidence-Based Guidelines for CVD Prevention in Women
CV Mortality Risk With NCEP-MetS vs WHO-MetS
Updated Criteria for Clinical Diagnosis of Metabolic Syndrome
Statin Advisory: Definitions of Muscle Toxicity
Statin Advisory: Monitoring Parameters, Follow-Up Schedule
Statin Advisory: Risk Factors for Statin-Associated Myopathy
Statin Advisory: Conclusions
ADA: Glycemic Control, BP, and Lipid Targets in Type 2 Diabetes
Consensus Recommendations for Lp-PLA2 Testing


Clinical Trials
A-F
Lp(a): An Independent CHD Risk Factor in Men of the Framingham Offspring Cohort
Lp(a): Vascular Events by Sex and Quintile at Baseline (Cardiovascular Health Study)
AFCAPS/TexCAPS: RR of Acute Coronary Events—LDL-C and Homocysteine
CARE: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
CARE: Fatal CHD or Nonfatal MI (Primary End Point)
CARE: Findings From a Post Hoc Analysis
CARE: Impact of Drug Therapy on Lipids and Lipoproteins in Older Patients With MI
CARE: Reduction in Coronary Events, Revascularizations, and Stroke in Older Adults With MI and Average Cholesterol Levels
CARE: Incidence of Coronary Events in Younger Versus Older Patients
CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
Diabetes Prevention Program
AVERT: Study Design and Inclusion Criteria
AVERT: Major Exclusion Criteria
AVERT: Overview of Study Procedures
AVERT: Secondary Efficacy Assessments
AVERT: Baseline Patient Characteristics
AVERT: Ischemic Events
AVERT: Ischemic Events
AVERT: Time to First Ischemic Event
AVERT: Summary of Lipid Parameters
AVERT: Incidence of First Ischemic Event by Time
AVERT: Safety Evaluation
ALLHAT-LLT: All-Cause Mortality
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
ASCOT–LLA: Study Design
ASCOT-LLA: Primary End Point in Subgroups
ASCOT-LLA: Secondary End Points
ASCOT-LLA: Effect of Atorvastatin vs Placebo on CV and Coronary End Points
FIELD: Fenofibrate Effect on Lipids
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
Abnormal Lipid Levels in Men With Type 2 Diabetes
Abnormal Lipid Levels in Women With Type 2 Diabetes
CARE: Major Coronary Events in the Diabetic Subgroup
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
CARDS: Effect of Treatment on Primary and Secondary End Points
CARDS: Effect of Treatment on Primary End Point by Lipid Level
ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
ACCORD Eye: Moderate Vision Loss by Treatment Group at Year 4
G-L
LRC Follow-up Study: CVD Mortality by Non–HDL-C and LDL-C in Men
LRC Follow-up Study: CVD Mortality by Non-HDL-C and LDL-C in Women
L-TAP: Patient Success in Achieving Target LDL-C Levels
Lyon Diet Heart Study: Cumulative Survival Without Cardiac Death and Nonfatal MI
LIPID: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Diabetic Status
LIPID: Reduction in nonfatal MI and CHD Death Risk Stratified by Prerandomization Age
LIPID Trial Follow-Up: Cardiovascular Events Over 8 Years
LIPID Trial Follow-Up: Serious Adverse Events Over 8 Years
Fasting TG and Risk for CHD: Helsinki Heart Study
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
L-CAD: Comparison of End Points, Change in Lumen Diameters
IDEAL Study: Secondary End Points
IDEAL Study: Effect of Treatment on LDL-C
JPAD: Study Design
JPAD Results: Primary Endpoint (CVD Composite)
JPAD Results: Primary Endpoint in Subgroups
M-R
NOMAS: Study Design
NOMAS: Event-Free Curves Based on MetSyn and Endothelial Dysfunction
MESA: Study Design
MESA: CVD and CHD Risk by CIMT or CAC Score
PREMIER: Percentage of All Participants With Hypertension (6 mo)
JNC 7: Classification and Management of Blood Pressure for Adults
PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis
PDAY: Prevalence of lesions in LAD
PDAY: Prevalence of Risk Factors
PDAY: Prevalence of Lesions by Smoking and Non-HDL-C Status
Age-Adjusted Total Cholesterol Levels in NHANES III vs NHANES 1999-2000
NHANES I Epidemiologic Follow-up Study: CHD Incidence and Survival in African American Men and Women
Adult Population Not Reaching LDL-C Targets
Prevalence of Overweight in US Men: NHANES 1999-2000
Prevalence of Overweight in US Women: NHANES 1999-2000
Prevalence of Obesity in US Men: NHANES 1999-2000
Prevalence of Obesity in US Women: NHANES 1999-2000
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
Post-CABG Study: Aggressive vs Moderate Treatment
Post-CABG: End Points, Results, Conclusions
Post-CABG Angiographic Outcomes
Post-CABG: Event Rates by Cholesterol Group
PROSPER: Secondary End Point Results
PROSPER: Rate of CHD-Related Death
Hypertriglyceridemia—An Independent Risk Factor for CHD: PROCAM Study
Fasting TG and Risk for CHD Death: Paris Prospective Study
CHD Mortality and Hyperinsulinemia: Paris Prospective Study (N=943)
Relation Between Baseline Fasting Insulin and Ischemic Heart Disease
NHANES III: Age-Adjusted Prevalence of Individual Risk Factors for the Metabolic Syndrome
NHANES III: Age-Adjusted Prevalence of >3 Risk Factors for the Metabolic Syndrome
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
MIRACL: Study Rationale
MIRACL: Study Design
MIRACL: Major Exclusion Criteria
MIRACL: Outcome Measures
MIRACL: Baseline Patient Characteristics
MIRACL: Change in Lipid Levels
MIRACL: Time to First Ischemic Event
MIRACL: Occurrence of Primary Combined End Point
MIRACL: Fatal or Nonfatal Stroke
PRISM: Event Rate Curves
PROVE-IT: Median LDL-C Levels During Study
PREDICT: Study Design
PREDICT: Primary Endpoint Event Rates in Successive Categories of CAC Score
PROSPER: Association of Leptin With Diabetes
PROSPER: Association of Leptin With CVD
S-Z
SHEEP: Risk Factors for Nonfatal MI in Men and Women
WISE: Prevalence of Angiographic CAD Based on BMI, Metabolic Status
Cholesterol and CHD: Seven Countries Study
Effect of Lifestyle Changes on Angiographic CAD
Treating to New Targets: Mean Lipid Levels
TNT: Hazard Ratios for the Primary Outcome
TNT: Hazard Ratios for Primary Outcome Components
TNT: Hazard Ratios for Secondary Outcomes
TNT: Safety Profile
SPARCL Primary Outcome: Fatal or Nonfatal Stroke
Prevalence of Macrovascular Disease and CHD According to Quintiles of Fasting C-Peptide
Swedish Register Study Design and Baseline Characteristics
Swedish Register Study: Early Statin Treatment Improves Post-AMI Survival Rates
The Strong Heart Study: Differences in CVD Risk Factors by Diabetic Status in Men and Women
WESDR: Hyperglycemia and the Risk for Vascular Complications in Older-Onset Diabetes
WESDR: Hyperglycemia and the Risk for Cause-Specific CVD Mortality
UKPDS: Intensive Blood-Glucose vs Conventional Treatment in Patients With Type 2 Diabetes
UKPDS: Tight Blood Pressure Control vs Less Tight Control in Patients With Type 2 Diabetes
Strong Heart Study: Non–HDL-C as CVD Risk Predictor in Patients With Diabetes
Strong Heart Study: Non–HDL-C Compared With Other CVD Risk Predictors
Steno-2: Effect of Therapies on Selected Risk Factors
Steno-2 Study: Primary Composite End Point or Surgery for PAD
Women’s Health Study: Association of Fasting and Nonfasting Lipids With CVD


Nonpharmacologic Therapies
Diet
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
Diabetes Prevention Program
AVERT: Overview of Study Procedures
L-TAP: Patient Success in Achieving Target LDL-C Levels
Lyon Diet Heart Study: Cumulative Survival Without Cardiac Death and Nonfatal MI
Effect of Lifestyle Changes on Angiographic CAD
Trans-Fatty Acid Intake and Relative Risk for CHD
ATP III: Features Shared With ATP II
ATP III: Nutritional Components of the TLC Diet
ATP III: Additional Dietary Options for LDL-C Lowering
ATP III: Management of Elevated TG
Statin Advisory: Risk Factors for Statin-Associated Myopathy
Potential Mortality Reduction With Lifestyle/Dietary Changes
Fruit/Vegetable Consumption: Effects on Stroke Risk Reduction
Reduced Intake of Trans-Fatty Acids: Estimated Effects on CHD
Effects of Drug Therapy and Diet on Lipids
Wine Consumption and CHD
Impact on TG Following Dietary Restrictions
TG Metabolism in CHD: Studies in the Postprandial State
Nonpharmacological Approaches to TG Lowering
Benefits of Intensive Lifestyle Changes on TG Levels
Exercise
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
Diabetes Prevention Program
Effect of Lifestyle Changes on Angiographic CAD
ATP III: Features Shared With ATP II
ATP III: Management of Elevated TG
Potential Mortality Reduction With Lifestyle/Dietary Changes
Effects of Drug Therapy and Diet on Lipids
Nonpharmacological Approaches to TG Lowering
Benefits of Intensive Lifestyle Changes on TG Levels
Prevalence and CVD Correlates of Low Cardiorespiratory Fitness
Metabolic Syndrome and Cardiorespiratory Fitness
Other
AVERT: Study Design and Inclusion Criteria
AVERT: Major Exclusion Criteria
AVERT: Overview of Study Procedures
AVERT: Secondary Efficacy Assessments
AVERT: Baseline Patient Characteristics
AVERT: Ischemic Events
AVERT: Time to First Ischemic Event
AVERT: Summary of Lipid Parameters
AVERT: Incidence of First Ischemic Event by Time
AVERT: Safety Evaluation
JNC 7: Classification and Management of Blood Pressure for Adults
Nonpharmacological Approaches to TG Lowering


Pharmacologic Therapies: Blood Pressure Management
Blood Pressure Management
ALLHAT-LLT: All-Cause Mortality
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
ASCOT–LLA: Study Design
ASCOT-LLA: Primary End Point in Subgroups
UKPDS: Tight Blood Pressure Control vs Less Tight Control in Patients With Type 2 Diabetes
JNC 7: Treatment Algorithm for Hypertension
Effect of Monotherapy, Combination Therapy on Blood Pressures
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
ACCORD Eye: Moderate Vision Loss by Treatment Group at Year 4
ADHERE: Long-Term Medication Use
CHARM: ARBs in Heart Failure
CHARM-Overall: Design, Hypothesis, and Baseline Characteristics
CHARM-Overall: Primary Endpoint (CV and Non-CV Death)
CHARM-Alternative: Primary Endpoint
DECODE: IFG and IGT Are Associated With Increased Mortality Rate
East-West Study: 7-Year Incidence of Fatal and Nonfatal MI in Type 2 Diabetes and CHD
EPHESUS: Death Rate From CV Causes or Hospitalization for CV Events
IRAS: CVD Risk Factors Are Also Risk Factors for Type 2 Diabetes
Meta-Analysis: Overlap in Racial Response to Antihypertensives
PREMIER: Study Design
PREMIER: Lifestyle Modification Success Rates
PREMIER: Study Results
Albuminuria as Independent Risk Factor for Mortality in Type 2 Diabetes
ATP III: Management of Diabetic Dyslipidemia
ATP III: The Metabolic Syndrome Diagnosis Established When ≥3 Risk Factors Are Present
Diabetes: The Most Common Cause of ESRD
Diabetes and CVD
East-West Study: 7-Year Incidence of Fatal and Nonfatal MI in Type 2 Diabetes and CHD
Elevated Risk of CVD Prior to Clinical Diagnosis of Type 2 Diabetes
Relationship Between Estimated GFR and Cardiovascular Outcome
Stroke Mortality Rate vs Usual Blood Pressure
Classification of Heart Failure: ACC/AHA Stage vs NYHA Class
DASH Diet
ISHIB: Hypertension Treatment in African Americans
ISHIB Recommendations for African-Americans With High BP
JNC 7: Hypertension Treatment Algorithm
JNC 7: Lifestyle Modifications to Manage Hypertension
Recommended Treatment of Hypertension in Diabetes
Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines
K/DOQI Guidelines: Estimating GFR
Microalbuminuria and Macroalbuminuria
National Kidney Foundation: Stages and Prevalence of CKD (Age >20 Years)
Risk Factors for Proteinuria in CKD
Screening for Proteinuria
Women’s Health Initiative: Total Energy Expenditure From Walking
JNC 7: Considerations for Special Populations
Cardiovascular Disease Continuum
Death Rates From Hypertension
Forecasted Increases in Worldwide Hypertension Prevalence
From Risk Factors to Heart Failure
HF in African-Americans
HF Incidence in African-Americans by Age, Gender
Heart Failure Facts
Hypertension Awareness, Treatment, and Control: US 1976 to 2000
Hypertension Challenges in the Elderly
Hypertension Facts
Impact of High-Normal BP on CVD Risk in Women: Framingham Study
Overweight/Obesity: Mortality
Population-Attributable Risk* for Heart Failure Development
Role of Waist Circumference in Assessing Risk
Smoking: Mortality
Time-to-Benefit of Smoking Cessation After Last Cigarette
US Adults With HTN by Sex, Race, Ethnicity: NHANES 1988-1994 to 1999-2000
US Prevalence of Cardiovascular Diseases
Prevalence of Hypertension: NHANES, 1999–2000
Hypertension Largely Uncontrolled Across Ethnic Groups
Race/Ethnicity and HBP
Greater RR of Comorbid Conditions, Events in Blacks vs Whites
Hypertension in African Americans
Keys to Treating Hypertension in African-American Patients
In African Americans, Some Barriers to Hypertension Control Are Patient-Related
In African Americans, Some Barriers to Hypertension Control Are Physician-Related
RAS Blockade in Blacks
HTN in Hispanic Americans
Hypertension in Men: More Prevalent in Blacks
Hypertension in Women:More Prevalent in Blacks
Characteristics of Hypertension in African Americans
Blacks Have Higher CHD, Stroke Mortality Rates
Hypertension in Men: Prevalence in Hispanics Versus Whites
Hypertension in Women: Prevalence in Hispanics Versus Whites


Pharmacologic Therapies: Diabetes Management
Diabetes Management
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
Diabetes Prevention Program
ASCOT-LLA: Primary End Point in Subgroups
FIELD: Fenofibrate Effect on Lipids
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
CARE: Major Coronary Events in the Diabetic Subgroup
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
CARDS: Effect of Treatment on Primary and Secondary End Points
CARDS: Effect of Treatment on Primary End Point by Lipid Level
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
SPARCL: First Events
Odds of CVD by Disease Condition and CRP Level
Global Impact of Hyperglycemia: Ischemic Heart Disease and Stroke Mortality
Cardiovascular Mortality in Patients With Coronary Artery Disease by BMI
PROSPER: Association of Leptin With Diabetes
PROSPER: Association of Leptin With CVD
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
ACCORD Eye: Moderate Vision Loss by Treatment Group at Year 4


Pharmacologic Therapies: Lipid Management
Bile-Acid Sequestrants
L-TAP: Patient Success in Achieving Target LDL-C Levels
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
L-CAD: Comparison of End Points, Change in Lumen Diameters
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
Post-CABG Study: Aggressive vs Moderate Treatment
Post-CABG: End Points, Results, Conclusions
Post-CABG Angiographic Outcomes
Post-CABG: Event Rates by Cholesterol Group
Colesevelam, Atorvastatin—Effects on Lipids
Cholesterol-Absorption Inhibitors
Effect of Ezetimibe Monotherapy on Lipids in Patients With Primary Hypercholesterolemia
Effect of Ezetimibe + Atorvastatin on Lipids in Primary Hypercholesterolemia
Effect of Ezetimibe + Simvastatin on Lipids in Primary Hypercholesterolemia
Effect of Ezetimibe + Lovastatin on Lipids in Primary Hypercholesterolemia
Fibric Acids
FIELD: Fenofibrate Effect on Lipids
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
L-TAP: Patient Success in Achieving Target LDL-C Levels
Fasting TG and Risk for CHD: Helsinki Heart Study
Fasting TG and Risk for CHD Death: Paris Prospective Study
ATP III: Management of Elevated TG
Statin Advisory: Risk Factors for Statin-Associated Myopathy
Colesevelam, Atorvastatin—Effects on Lipids
Clinical Benefits of Cholesterol Reduction
ATP III: Management of Low HDL-C
Incidence of Myopathy in 3 UK Cohorts
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
ACCORD Eye: Moderate Vision Loss by Treatment Group at Year 4
Nicotinic Acid
L-TAP: Patient Success in Achieving Target LDL-C Levels
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
L-CAD: Comparison of End Points, Change in Lumen Diameters
ATP III: Management of Elevated TG
Statin Advisory: Risk Factors for Statin-Associated Myopathy
ATP III: Management of Low HDL-C
Omega-3 Fatty Acids
Omega-3 Concentrate: Effects on Lipids
Omega-3 Concentrate Plus Statin: Effects on TG
P-OM3 Plus Simvastatin: Study Design
P-OM3 Plus Simvastatin: Changes in Lipids and Lipoprotein Particles From Baseline
Statins
AFCAPS/TexCAPS: RR of Acute Coronary Events—LDL-C and Homocysteine
CARE: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
CARE: Fatal CHD or Nonfatal MI (Primary End Point)
CARE: Findings From a Post Hoc Analysis
CARE: Impact of Drug Therapy on Lipids and Lipoproteins in Older Patients With MI
CARE: Reduction in Coronary Events, Revascularizations, and Stroke in Older Adults With MI and Average Cholesterol Levels
CARE: Incidence of Coronary Events in Younger Versus Older Patients
AVERT: Study Design and Inclusion Criteria
AVERT: Overview of Study Procedures
AVERT: Secondary Efficacy Assessments
AVERT: Baseline Patient Characteristics
AVERT: Ischemic Events
AVERT: Ischemic Events
AVERT: Time to First Ischemic Event
AVERT: Summary of Lipid Parameters
AVERT: Incidence of First Ischemic Event by Time
AVERT: Safety Evaluation
ALLHAT-LLT: All-Cause Mortality
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
ASCOT–LLA: Study Design
ASCOT-LLA: Primary End Point in Subgroups
ASCOT-LLA: Secondary End Points
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
CARDS: Effect of Treatment on Primary and Secondary End Points
ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C
L-TAP: Patient Success in Achieving Target LDL-C Levels
LIPID: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Diabetic Status
LIPID: Reduction in nonfatal MI and CHD Death Risk Stratified by Prerandomization Age
LIPID Trial Follow-Up: Cardiovascular Events Over 8 Years
LIPID Trial Follow-Up: Serious Adverse Events Over 8 Years
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
L-CAD: Comparison of End Points, Change in Lumen Diameters
IDEAL Study: Secondary End Points
IDEAL Study: Effect of Treatment on LDL-C
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
Post-CABG Study: Aggressive vs Moderate Treatment
Post-CABG: End Points, Results, Conclusions
Post-CABG Angiographic Outcomes
Post-CABG: Event Rates by Cholesterol Group
PROSPER: Secondary End Point Results
PROSPER: Rate of CHD-Related Death
MIRACL: Study Design
MIRACL: Major Exclusion Criteria
MIRACL: Outcome Measures
MIRACL: Baseline Patient Characteristics
MIRACL: Change in Lipid Levels
MIRACL: Time to First Ischemic Event
MIRACL: Occurrence of Primary Combined End Point
MIRACL: Fatal or Nonfatal Stroke
PRISM: Event Rate Curves
PROVE-IT: Median LDL-C Levels During Study
Treating to New Targets: Mean Lipid Levels
TNT: Hazard Ratios for the Primary Outcome
TNT: Hazard Ratios for Primary Outcome Components
TNT: Hazard Ratios for Secondary Outcomes
TNT: Safety Profile
SPARCL Primary Outcome: Fatal or Nonfatal Stroke
Swedish Register Study Design and Baseline Characteristics
Swedish Register Study: Early Statin Treatment Improves Post-AMI Survival Rates
Trends in Total Cholesterol for US Adults, 1960-1962 to 1999-2002
TGs Predict CAD Risk Independently of TC and HDL-C
Association of Small, Dense LDL With Myocardial Infarction
ATP III: Special Populations—Women, Middle-Aged Men
Statin Advisory: Definitions of Muscle Toxicity
Statin Advisory: Monitoring Parameters, Follow-Up Schedule
Statin Advisory: Risk Factors for Statin-Associated Myopathy
Statin Advisory: Conclusions
Colesevelam, Atorvastatin—Effects on Lipids
Effect of Ezetimibe + Atorvastatin on Lipids in Primary Hypercholesterolemia
Effect of Ezetimibe + Simvastatin on Lipids in Primary Hypercholesterolemia
Effect of Ezetimibe + Lovastatin on Lipids in Primary Hypercholesterolemia
Clinical Benefits of Cholesterol Reduction
Incidence of Myopathy in 3 UK Cohorts
Omega-3 Concentrate Plus Statin: Effects on TG
PROVE-IT Substudy: Primary Endpoint and Achieved LDL-C Levels
Switching Statins: Effects on Compliance and Persistence
Phenotypic Predictors of Response to Simvastatin
Effect of Cholesterol Lowering on Stroke Events: A Meta-analysis of Statin Trials
Effects of Statins on Stroke Events: A Meta-analysis of Primary- and Secondary-Prevention Trials
Impact of Lowering LDL-C on CVD Events and Total Mortality
Relation Between CHD Events and LDL-C Outcomes in Statin Trials
Atorvastatin: Percent of Patients With >1 Adverse Event (Pooled Analysis: Fixed-Dose Data Grouping)
Atorvastatin Dose-Response Relationship in Primary Hypercholesterolemia
Impact of Atorvastatin on Lipids in Patients With Hypertriglyceridemia
Association of Small, Dense LDL With Insulin Resistance
Statin Trials: Therapy Reduces Major Coronary Events in Women
P-OM3 Plus Simvastatin: Study Design
P-OM3 Plus Simvastatin: Changes in Lipids and Lipoprotein Particles From Baseline
PROSPER: Association of Leptin With CVD
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye: Substudy of ACCORD
ACCORD Eye: Progression of Diabetic Retinopathy By Treatment Group at Year 4
ACCORD Eye: Moderate Vision Loss by Treatment Group at Year 4


Pharmacologic Therapies: Other
Pharmacologic Therapies Other
CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients
JPAD: Study Design
JPAD Results: Primary Endpoint (CVD Composite)
JPAD Results: Primary Endpoint in Subgroups
NHANES I Epidemiologic Follow-up Study: CHD Incidence and Survival in African American Men and Women
Swedish Register Study Design and Baseline Characteristics
ATP III: LDL-C Measurements in Patients Hospitalized for Major Coronary Events
Statin Advisory: Risk Factors for Statin-Associated Myopathy
Effects of Drug Therapy and Diet on Lipids
Impact of Atorvastatin on Lipids in Patients With Hypertriglyceridemia
PROSPER: Association of Leptin With Diabetes


Special Populations
Patients With Diabetes
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
Diabetes Prevention Program
ASCOT-LLA: Primary End Point in Subgroups
FIELD: Fenofibrate Effect on Lipids
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
Abnormal Lipid Levels in Men With Type 2 Diabetes
Abnormal Lipid Levels in Women With Type 2 Diabetes
CARE: Major Coronary Events in the Diabetic Subgroup
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
CARDS: Effect of Treatment on Primary and Secondary End Points
CARDS: Effect of Treatment on Primary End Point by Lipid Level
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Diabetic Status
JPAD Results: Primary Endpoint in Subgroups
CHD Mortality and Hyperinsulinemia: Paris Prospective Study (N=943)
Relation Between Baseline Fasting Insulin and Ischemic Heart Disease
NHANES III: Age-Adjusted Prevalence of Individual Risk Factors for the Metabolic Syndrome
NHANES III: Age-Adjusted Prevalence of >3 Risk Factors for the Metabolic Syndrome
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
PREDICT: Study Design
PREDICT: Primary Endpoint Event Rates in Successive Categories of CAC Score
Prevalence of Macrovascular Disease and CHD According to Quintiles of Fasting C-Peptide
The Strong Heart Study: Differences in CVD Risk Factors by Diabetic Status in Men and Women
Strong Heart Study: Non–HDL-C as CVD Risk Predictor in Patients With Diabetes
Strong Heart Study: Non–HDL-C Compared With Other CVD Risk Predictors
Progression to Atherosclerotic Clinical Events in Patients With Diabetes
Atherosclerosis in Diabetes
ATP III: The Metabolic Syndrome
ATP III: Management of Diabetic Dyslipidemia
Updated Criteria for Clinical Diagnosis of Metabolic Syndrome
ADA: Glycemic Control, BP, and Lipid Targets in Type 2 Diabetes
TG Metabolism in CHD: Studies in the Postprandial State
Association of Small, Dense LDL With Insulin Resistance
Mortality Rates for Ischemic Heart Disease in Patients With and Without Diabetes
Women, Diabetes, and CHD
Potential Mechanisms of Atherogenesis in Diabetes
PROSPER: Association of Leptin With Diabetes
PROSPER: Association of Leptin With CVD
Patients With Hypertension
ALLHAT-LLT: All-Cause Mortality
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
ASCOT–LLA: Study Design
ASCOT-LLA: Primary End Point in Subgroups
ASCOT-LLA: Effect of Atorvastatin vs Placebo on CV and Coronary End Points
JNC 7: Classification and Management of Blood Pressure for Adults
UKPDS: Tight Blood Pressure Control vs Less Tight Control in Patients With Type 2 Diabetes
JNC 7: Treatment Algorithm for Hypertension
Effect of Monotherapy, Combination Therapy on Blood Pressures
Lifestyle Modification: Effect on CVD Risk Factors (DPP)
Women
AHA Evidence-Based Guidelines for CVD Prevention in Women (cont'd)
Abnormal Lipid Levels in Women With Type 2 Diabetes
LRC Follow-up Study: CVD Mortality by Non-HDL-C and LDL-C in Women
LIPID: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
NHANES I Epidemiologic Follow-up Study: CHD Incidence and Survival in African American Men and Women
Prevalence of Overweight in US Women: NHANES 1999-2000
Prevalence of Obesity in US Women: NHANES 1999-2000
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
SHEEP: Risk Factors for Nonfatal MI in Men and Women
WISE: Prevalence of Angiographic CAD Based on BMI, Metabolic Status
The Strong Heart Study: Differences in CVD Risk Factors by Diabetic Status in Men and Women
WISE Study: Review of Ischemic Heart Disease in Women
ATP III: Features Shared With ATP II
ATP III: Special Populations—Women, Middle-Aged Men
ATP III Framingham Risk Scoring–Assessing CHD Risk in Women
ATP III Framingham Risk Scoring–Step 7: CHD Risk for Women
AHA Evidence-Based Guidelines for CVD Prevention in Women
Statin Advisory: Risk Factors for Statin-Associated Myopathy
Women, Diabetes, and CHD
Leading Causes of Death for US Females, 2001
CVD Mortality Trends for US Males and Females
ATP III: Special Populations—Older Adults, Younger Adults
ATP III vs ATP II: Increases in Treatment-Eligible Primary-Prevention Patients
Adjusted Relative Risk for First Cardiovascular Event Based on CRP, LDL-C
Event-Free Survival With CRP, LDL-C Levels Above or Below the Median
Awareness and Preventive Action for Cardiovascular Health in Women
Statin Trials: Therapy Reduces Major Coronary Events in Women
CHD in the United States
Women’s Health Study: Design
Women’s Health Study: Association of Fasting and Nonfasting Lipids With CVD
Defining Normal Distributions of CAC Framingham Cohorts
Younger/Older Patients
CARE: Impact of Drug Therapy on Lipids and Lipoproteins in Older Patients With MI
CARE: Reduction in Coronary Events, Revascularizations, and Stroke in Older Adults With MI and Average Cholesterol Levels
CARE: Incidence of Coronary Events in Younger Versus Older Patients
ASCOT-LLA: Primary End Point in Subgroups
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
LIPID: Reduction in nonfatal MI and CHD Death Risk Stratified by Prerandomization Age
PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis
PDAY: Prevalence of lesions in LAD
PDAY: Prevalence of Risk Factors
PDAY: Prevalence of Lesions by Smoking and Non-HDL-C Status
Age-Adjusted Total Cholesterol Levels in NHANES III vs NHANES 1999-2000
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
WESDR: Hyperglycemia and the Risk for Vascular Complications in Older-Onset Diabetes
WESDR: Hyperglycemia and the Risk for Cause-Specific CVD Mortality
Composite CIMT With Metabolic Syndrome in Young Adults
ATP III: Features Shared With ATP II
ATP III: Special Populations—Women, Middle-Aged Men
Statin Advisory: Risk Factors for Statin-Associated Myopathy
ATP III vs ATP II: Increases in Treatment-Eligible Primary-Prevention Patients
CHD in the United States
Elevated TC Effects on Risk of CHD Death in Younger Men: A Meta-Analysis
PROSPER: Association of Leptin With Diabetes
PROSPER: Association of Leptin With CVD
Multiethnic Patients
NOMAS: Study Design
NOMAS: Event-Free Curves Based on MetSyn and Endothelial Dysfunction
MESA: Study Design
MESA: CVD and CHD Risk by CIMT or CAC Score


Atherogenic Dyslipidemia
Didactic
Atherogenic Dyslipidemia in Obesity, Insulin Resistance, MetSyn
Residual Cardiovascular Risk in Major Statin Trials
TGs and CHD Risk: Meta-Analysis of 29 Studies in Western Populations
Association of TG Levels and Incident CVD According to Fasting Status
Risk for MI, IHD, and Total Death by Nonfasting TG Increases
Non–HDL-C and CVD Risk
CHD Risk: HDL-C Versus LDL-C as Predictor
Statin Therapy Does Not Eliminate CVD Risk Associated With Low HDL-C
Underestimation of Number of LDL Particles With Increased Small LDL
TRIMS: Increased LDL Particle Size With Fenofibrate in HyperTG Patients Is Associated With End-of-Treatment TG
Look AHEAD: Improvement in Metabolic Syndrome Components at 1 Year
Pharmacologic Options for Managing Atherogenic Dyslipidemia
Coronary Drug Project: Niacin Effects on CVD, Mortality
HHS: Primary Prevention With Gemfibrozil
VA-HIT: Effect of Gemfibrozil on Primary Endpoint, Lipids
VA-HIT: LDL, HDL Particle Numbers Are Significant, Independent Predictors of New CHD Events
FIELD: End of Study Lipid Results
FIELD: Primary and Secondary Endpoints
Omega-3 Acid Ethyl Esters: Secondary-Prevention Studies
GISSI-Prevenzione: Time Course of Clinical Events
Omega-3 Acid Ethyl Esters: Lipid Effects in Patients with TG>500 mg/dL
SAFARI: Combination Therapy in Patients With Combined Hyperlipidemia
SAFARI: Effects on LDL Particle Subclasses
Atorvastatin and Fenofibrate Alone or in Combination in Patients With Type 2 Diabetes
Statin-Fibrate Combination Therapy: Pharmacokinetic Interactions
Lovastatin ± Niacin: Lipid Effects
HATS: Angiographic and Clinical Endpoints After 3 Years
Omega-3 Acid Ethyl Esters in Combination With Atorvastatin
Omega-3 Acid Ethyl Esters and Simvastatin in Patients With Combined Hyperlipidemia
COMBOS: Omega-3 Acid Ethyl Esters and Simvastatin in Patients with High TGs
JELIS: Incidence of Coronary Events
ATP III: Management of Elevated TG
Case Study
AHA Scientific Statement on Omega-3 Acid Ethyl Esters Intake


Risk Assessment
Risk Assessment
MESA: Study Design
MESA: CVD and CHD Risk by CIMT or CAC Score
PREDICT: Study Design
PREDICT: Primary Endpoint Event Rates in Successive Categories of CAC Score
Prediction of CV Events and Mortality Using ABI and FRS
Effect of Inclusion of ABI on 10-Year Cardiovascular Mortality
Association of Subclinical Atherosclerosis With FRS
Relation of Subclinical Atherosclerosis With Family History of Premature CAD
Average Carotid Wall Thicknessa in First-Degree Relatives Vs Controlsb
Consensus Recommendations for Lp-PLA2 Testing
Women’s Health Study: Design
Defining Normal Distributions of CAC Framingham Cohorts
Defining Normal Distributions of CAC: Participant Characteristics
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C: 5-Year Follow-Up
Relationship of Elevated LDL-C and Systolic BP With CAC
Prevalence of CAC Based on LDL-C Tertilesa Across SBP Levels